David Lebwohl Intellia Therapeutics, Inc. (NTLA) insider trading activity

NTLA Quotes by TradingView

David Lebwohl is EVP, Chief Medical Officer of Intellia Therapeutics, Inc.. Currently has a direct ownership of 130,866 shares of NTLA, which is worth approximately $1.06 Million. The most recent transaction as insider was on Mar 01, 2025, when has been sold 43,200 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 131K
34.6% 3M change
40.61% 12M change
Total Value Held $1.06 Million

David Lebwohl Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 01 2025
BUY
Grant, award, or other acquisition
-
43,200 Added 24.82%
130,866 Common Stock
Jan 03 2025
SELL
Open market or private sale
$116,404 $12.18 p/Share
9,557 Reduced 9.83%
87,666 Common Stock
Jan 01 2025
BUY
Exercise of conversion of derivative security
-
3,189 Added 3.18%
97,223 Common Stock
Mar 01 2024
BUY
Grant, award, or other acquisition
-
38,701 Added 29.37%
93,073 Common Stock
Jan 03 2024
SELL
Open market or private sale
$172,134 $29.46 p/Share
5,843 Reduced 9.7%
54,372 Common Stock
Jan 01 2024
BUY
Exercise of conversion of derivative security
-
3,187 Added 5.03%
60,215 Common Stock
Mar 01 2023
BUY
Grant, award, or other acquisition
-
30,674 Added 35.24%
56,361 Common Stock
Jan 04 2023
SELL
Open market or private sale
$95,778 $37.21 p/Share
2,574 Reduced 9.11%
25,687 Common Stock
Jan 01 2023
BUY
Exercise of conversion of derivative security
-
3,187 Added 10.13%
28,261 Common Stock
Mar 01 2022
BUY
Grant, award, or other acquisition
-
13,816 Added 35.84%
24,738 Common Stock
Jan 01 2022
SELL
Open market or private sale
$117,964 $112.24 p/Share
1,051 Reduced 8.78%
10,922 Common Stock
Jan 01 2022
BUY
Exercise of conversion of derivative security
-
3,187 Added 21.02%
11,973 Common Stock
Nov 05 2021
SELL
Open market or private sale
$320,256 $133.44 p/Share
2,400 Reduced 21.59%
8,714 Common Stock
Nov 05 2021
BUY
Exercise of conversion of derivative security
$30,288 $12.62 p/Share
2,400 Added 17.76%
11,114 Common Stock
Oct 14 2021
SELL
Open market or private sale
$309,144 $128.81 p/Share
2,400 Reduced 21.59%
8,714 Common Stock
Oct 14 2021
BUY
Exercise of conversion of derivative security
$30,288 $12.62 p/Share
2,400 Added 17.76%
11,114 Common Stock
Sep 24 2021
BUY
Exercise of conversion of derivative security
$99,988 $12.62 p/Share
7,923 Added 47.62%
8,714 Common Stock
Sep 21 2021
SELL
Open market or private sale
$359,544 $149.81 p/Share
2,400 Reduced 75.21%
791 Common Stock
Sep 21 2021
BUY
Exercise of conversion of derivative security
$30,288 $12.62 p/Share
2,400 Added 42.93%
3,191 Common Stock
Aug 30 2021
SELL
Open market or private sale
$378,720 $157.8 p/Share
2,400 Reduced 75.21%
791 Common Stock
Aug 30 2021
BUY
Exercise of conversion of derivative security
$30,288 $12.62 p/Share
2,400 Added 42.93%
3,191 Common Stock
Aug 09 2021
SELL
Open market or private sale
$393,720 $164.05 p/Share
2,400 Reduced 75.21%
791 Common Stock
Aug 09 2021
BUY
Exercise of conversion of derivative security
$30,288 $12.62 p/Share
2,400 Added 42.93%
3,191 Common Stock
DL

David Lebwohl

EVP, Chief Medical Officer
Cambridge, MA

Track Institutional and Insider Activities on NTLA

Follow Intellia Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NTLA shares.

Notify only if

Insider Trading

Get notified when an Intellia Therapeutics, Inc. insider buys or sells NTLA shares.

Notify only if

News

Receive news related to Intellia Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on NTLA